An approach toward the syntheses of triazolo benzoxazines,triazolo quinoxalines,triazolo benzodiazepines,triazolo benzoxazepines,and triazolo benzothiazines via a simple and convenient protocol using basic alumina as solid support

A microwave assisted green protocol for the syntheses of triazole fused benzoxazines, benzoxazepines, quinoxalines, and benzothiazines was investigated using basic alumina as solid support. The one-pot reaction was carried out using Cu(phen)(PPh₃)Br as a catalyst. The protocol did not require the use of any additional ligands, base or the use of expensive and toxic palladiums.     

Benzodiazepines: Drugs with Chemical Skeletons Suitable for the Preparation of Metallacycles with Potential Pharmacological Activity

The synthesis of organometallic compounds with potential pharmacological activity has attracted the attention of many research groups, aiming to take advantage of aspects that the presence of the metal-carbon bond can bring to the design of new pharmaceutical drugs. In this context, we have gathered studies reported in the literature in which psychoactive benzodiazepine drugs were used as ligands in the preparation of organometallic and metal complexes and provide details on some of their biological effects. We also highlight that most commonly known benzodiazepine-based drugs display molecular features that allow the preparation of metallacycles via C-H activation. These organometallic compounds merit further attention regarding their potential biological effects, not only in terms of psychoactive drugs but also in the search for drug replacements, for example, for cancer treatments.     

UPLC - ESI MS/MS法测定动物饲料中苯二氮卓类药物

建立了超高效液相色谱-电喷雾串联质谱(UPLC - ESI MS/MS)同时检测动物饲料中地西泮、奥沙西泮、硝西泮、三唑仑、艾司唑仑和咪达唑仑6种苯二氮卓类药物的方法.饲料样品采用碱性叔丁基甲醚提取,Oasis MCX固相萃取柱净化,反相色谱柱分离,以0.1％甲酸和乙腈为流动相进行梯度洗脱,正离子模式扫描,多反应监测模...     

Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics

The appearance of pyrazolam in Internet shops selling ‘research chemicals’ in 2012 marked the beginning of designer benzodiazepines being sold as recreational drugs or ‘self medication’. With recent changes in national narcotics laws in many countries, where two uncontrolled benzodiazepines (phenazepam and etizolam), which were marketed by pharmaceutical companies in some countries, were scheduled, clandestine laboratories seem to turn to poorly characterized research drug candidates as legal substitutes. Following the appearance of pyrazolam, it comes with no surprise that recently, flubromazepam (7‐bromo‐5‐(2‐fluorophenyl)‐1,3‐dihydro‐2H‐1,4‐benzodiazepin‐2‐one), a second designer benzodiazepine, was offered on the market. In this article, this new compound was characterized using nuclear magnetic resonance, gas chromatography‐mass spectrometry (GC–MS), liquid chromatography–mass spectrometry (LC–MS/MS) and liquid chromatography quadrupole time‐of‐flight MS (LC–Q–ToF–MS). Additionally, a study was carried out, in which one of the authors consumed 4 mg of flubromazepam to gain preliminary data on the pharmacokinetic properties and the metabolism of this compound. For this purpose, serum as well as urine samples were collected for up to 31 days post‐ingestion and analyzed applying LC–MS/MS and LC–Q‐ToF‐MS techniques. On the basis of this study, flubromazepam appears to have an extremely long elimination half‐life of more than 100 h. One monohydroxylated compound and the debrominated compound could be identified as the predominant metabolites, the first allowing a detection of a consumption for up to 28 days post‐ingestion when analyzing urine samples in our case. Additionally, various immunochemical assays were evaluated, showing that the cross‐reactivity of the used assay seems not to be sufficient for safe detection of the applied dose in urine samples, bearing the risk that it could be misused in drug‐withdrawal settings or in other circumstances requiring regular drug testing. Furthermore, it may be used in drug‐facilitated crimes without being detected. Copyright © 2013 John Wiley & Sons, Ltd.     

分散固相萃取-超高效液相色谱-串联质谱法测定水产品中5种硝基咪唑类和6种苯二氮卓类药物北大核心CSCD

建立了分散固相萃取-超高效液相色谱-串联质谱法同时测定水产品中5种硝基咪唑类和6种苯二氮卓类药物残留的方法。样品用1%(v/v)氨水乙腈提取,提取液经十八烷基键合硅胶(C18)和N-丙基乙二胺(PSA)吸附剂净化,在45℃下用氮气吹至近干,用1 mL甲醇-水(1∶9,v/v)溶液复溶,过0.22μm尼龙-66滤膜后用超高效液相色谱-串联质谱测定。目标化合物采用Kinetex F5色谱柱(100 mm×3.0 mm,2.6μm)分离,以0.1%(v/v)甲酸水溶液和甲醇作为流动相进行梯度洗脱,在电喷雾离子源(ESI)、正离子扫描和多反应监测(MRM)模式下进行测定,基质匹配外标法定量。结果表明,5种硝基咪唑类和6种苯二氮卓类药物在8.5 min内完成色谱分离分析,目标物在0.5~20μg/L范围内线性关系良好,相关系数均大于0.995,检出限和定量限分别为0.2~0.5μg/kg和0.5~1.0μg/kg。以草鱼、对虾和大黄鱼为样品基质,在3个不同的添加水平下,5种硝基咪唑类和6种苯二氮卓类药物的平均回收率为73.2%~110.6%,相对标准偏差(RSD)小于15%。本研究建立的方法具有简单、快速、灵敏度高和成本低等优势,可用于水产品中5种硝基咪唑类和6种苯二氮卓类药物的快速检测。该方法的建立为我国水产品质量安全相关监管部门同时监控水产品中硝基咪唑类和苯二氮卓类药物残留提供了技术支持。     

CoMFA and CoMSIA 3D-quantitative structure-activity relationship model on benzodiazepine derivatives, inhibitors of phosphodiesterase IV

Recently, we reported structurally novel PDE4 inhibitors based on 1,4-benzodiazepine derivatives. The main interest in developing bezodiazepine-based PDE4 inhibitors is in their lack of adverse effects of emesis with respect to rolipram-like compounds. A large effort has thus been made toward the structural optimization of this series. In the absence of structural information on the inhibitor binding mode into the PDE4 active site, 2D-QSAR (H-QSAR) and two 3D-QSAR (CoMFA and CoMSIA) methods were applied to improve our understanding of the molecular mechanism controlling the PDE4 affinity of the benzodiazepine derivatives. As expected, the CoMSIA 3D contour maps have provided more information on the benzodiazepine interaction mode with the PDE4 active site whereas CoMFA has built the best tool for activity prediction. The 2D pharmacophoric model derived from CoMSIA fields is consistent with the crystal structure of the PDE4 active site reported recently. The combination of the 2D and 3D-QSAR models was used not only to predict new compounds from the structural optimization process, but also to screen a large library of bezodiazepine derivatives.     

Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization

A liquid chromatographic/mass spectrometric assay with atmospheric pressure chemical ionization (LC/APCI-MS) is presented for fast and reliable screening and identification and also for precise and sensitive quantification in plasma of the 23 benzodiazepines alprazolam, bromazepam, brotizolam, camazepam, chlordiazepoxide, clobazam, clonazepam, diazepam, flunitrazepam, flurazepam, desalkylflurazepam, lorazepam, lormetazepam, medazepam, metaclazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, temazepam and tetrazepam, triazolam, their antagonist flumazenil and the benzodiazepine BZ1 (omega 1) receptor agonists zaleplone, zolpidem and zopiclone. It allows confirmation of the diagnosis of an overdose situation and monitoring of psychiatric patients' compliance. The analytes were isolated from plasma using liquid-liquid extraction and were separated on a Merck LiChroCART column with Superspher 60 RP Select B as the stationary phase. Gradient elution was performed using aqueous ammonium formate and acetonitrile. After screening and identification in the scan mode using the authors' LC/MS library, the analytes were quantified in the selected-ion monitoring mode. The quantification assay was fully validated. It was found to be selective proved to be linear from sub-therapeutic to over therapeutic concentrations for all analytes, except bromazepam. The corresponding reference levels the assay's accuracy and precision data for all studied substances are listed. The accuracy and precision data were within the required limits with the exception of those for bromazepam. The analytes were stable in frozen plasma for at least 1 month. The validated assay was successfully applied to several authentic plasma samples from patients treated or intoxicated with various benzodiazepines or with zaleplone, zolpidem or zopiclone. It has proven to be appropriate for the isolation, separation, screening, identification and quantification of the drugs mentioned above in plasma for clinical toxicology, e.g. in cases of poisoning, and forensic toxicology, e.g. in cases of driving under the influence of drugs.     

A new approach for the solid-phase synthesis of pyrrolo[2,1-c][1,4]benzodiazepines involving reductive cleavage

A methodology based on reductive cleavage followed by cyclization, for the solid-phase synthesis of pyrrolo[2,1-c][1,4]benzodiazepines employing DIBAL-H, is described.